Ardelyx, Inc., a biopharmaceutical company, closed Monday’s regular session at $1.17 after surging 9.35% during the day. In the premarket session, ARDX stock further gained an increase of 5.98% and was trading at $1.24 at the last check.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
ARDX Launched IBSRELA
ARDX stock is on the rise following the launch of IBSRELA. Ardelyx announced on Monday that it would be launching IBSRELA, which is the only NHE3 inhibitor for treating Irritable Bowel Syndrome with Constipation. The approval of the drug is based on a set of successful phase 3 trials that involved more than 1200 patients having Irritable Bowel Syndrome. Both trials were able to meet their primary endpoints. IBSRELA is the first product of Ardelyx that is approved by the FDA.
Biopharma Industry Having Smooth Ride
Biopharmaceutical companies are long been considered among the most stable companies concerning investments, hence considered among the fastest-growing sectors. With the pandemic making us realize the importance of the healthcare system and medication products, the role of pharmaceutical companies has been on a rise. This ultimately is forcing the investors to jump the ships from other sectors toward pharma.
What Could Happen with ARDX?
Since its IPO, ARDX has plunged more than 91%. However, during the last month of 2021, ARDX announced that it would be launching IBSRELA sometime in 2022. Since then, investors are flocking in to buy the stock. The company hopes that IBSRELA would generate annual revenue of more than $500 million, making the company’s financial position stronger than ever before.
Looking ahead, the best strategy for the investor community is to invest for a longer period in ARDX stock instead of a short investment, which could prove to be a tricky scenario for them. Sure IBSRELA launch would provide an opportunity for investors to improve their returns, but this would not be the case in the immediate future. Hence, the best way to extract solid returns from the ARDX is via long-term investment.